Quality Investor
MarketsPortfolioEvidenceTestedCompareWatchlistAbout 

Azenta, Inc.

Rank #394StartupWatchlistCompare with other stocks

AZTA · Nasdaq · Healthcare

Azenta, Inc. (AZTA) — Rank #394 by gross profitability (GP/assets 0.14) · ROE -3.7% · Piotroski F-Score N/A.

As-of 2026-10-30 · CIK 0000933974 · all metrics point-in-time as of the filing date.

About

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.

Show more

It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc.

was founded in 1978 and is headquartered in Burlington, Massachusetts.

Industry
Medical Instruments & Supplies
Sector
Healthcare
State
DE
Filer Category
Large accelerated filer
Fiscal Year End
September 30
Website
azenta.com

Company Snapshot

P/S is the primary valuation lens for pre-profit companies.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

2,900

Industry

Medical Instruments & Supplies

Exchange

Nasdaq

11/11

Flags passed

AZTA passes 11/11 quality flags

  • PASS
    Gross margin holding
  • PASS
    Dilution within 2%
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Revenue not declining
  • PASS
    Operating margin holding
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Deferred revenue growing · Sequential beat (rev + EPS)

No data Balance sheet — not counted as a pass.

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.14
Return on equity
-3.7%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.24
Current ratio
2.50×
Net cash
$325.80M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
3.5%

Growth

2/2 pass
Revenue growth
3.6%
Piotroski F-Score
N/A
Share dilution
-13.7%

Burn rate (cash flow) is the primary read at this stage — TAM and product-market fit aren't metrics this dashboard tracks.

Profitability

Does it make money well?

No warning flags · GP/assets 4th percentile of 26 SIC 35 peers

Gross profitability (GP / assets)

0.14

Primary signal (Novy-Marx).

4th pctl of 26 SIC 35 peers

Return on equity

-3.7%

Gross margin

45.5%

64th pctl of 26 SIC 35 peers

Revenue growth (YoY)

3.6%

RPO growth (YoY)

-45.0%

Remaining performance obligations growth — RPO > revenue = forward demand building.

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

2.2%

Revenue CAGR (5Y)

8.9%

Earnings CAGR (3Y)

—

FCF CAGR (3Y)

—

Cash Flow Health

Is the cash real?

No warning flags · FCF 169% above net income

Free cash flow

$38.32M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

168.7%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

3.5%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

No warning flags · net cash $325.80M

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.24

100th pctl of 26 SIC 35 peers (best = lowest)

Current ratio

2.50×

72nd pctl of 26 SIC 35 peers

Quick ratio

1.72×

Net cash

$325.80M

Cash & equivalents minus total debt.

Piotroski F-Score

N/A

Only 8/9 components determinable.

Valuation

Is the price reasonable?

No warning flags

Capital allocation quality

Composite score

2.7 / 5

Fair
Share count trend(net buybacks)
-13.7%5/5 Strong
Buyback timing
N/AN/A
Dividend growth consistency(non-payer or broken streak)
0 yr3/5 Good
Net debt trajectory
N/A0/5 Weak

Lifecycle Phase History

20202025
Capital Return
Hypergrowth
Startup

Price History

AZTA-64.0% · -18.4% CAGRSPY+82.9% · +12.8% CAGR

View full financial statements →

Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports